From aidsmap: Generic PrEP for young, at-risk MSM
Generic PrEP for young, at-risk MSM in the US could be cost-saving and health-enhancing
Cost-effective generic oral PrEP for young men who have sex with men (MSM) in the US could end up reducing new HIV infections by 15% among those at highest risk, Alyssa Amick from Massachusetts General Hospital reported to the Conference on Retroviruses and Opportunistic Infections (CROI 2022) last week.
In the US, 13- to 24-year-olds made up approximately 20% of all new HIV diagnoses in 2019, while MSM accounted for just over two-thirds of those diagnosed. While the safety of oral HIV pre-exposure prophylaxis (PrEP) in the form of Truvada has been established for young MSM, the clinical and economic consequences of using PrEP in this at-risk group are uncertain, especially considering that they tend to have challenges adhering to PrEP and remaining in care.
The researchers aimed to compare initiation of PrEP and quarterly screening with annual HIV screening guidelines in terms of cost, cost-effectiveness and HIV incidence for young MSM at an increased risk of acquiring HIV. (Read full story on aidsmap)
[Credits: Shared on MSM Sexual Health - Asia.]